SynthesisCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2017
No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival.
Open access · greenAbstract readMeta-Analysis
In one paragraph
Synthesis in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 3 citations in OpenAlex.
- Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8Oncology letters · 2019Article
- A Call for Epidemiological Research on Myeloid-Derived Suppressor Cells in Ovarian Cancer: A Review of the Existing Immunological Evidence and Suggestions for Moving Forward.Frontiers in immunology · 2019Review
- Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients.Journal of neuro-oncology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
98 authors at 1 institution in 1 country.
Lara E Sucheston-CampbellCollege of Pharmacy, College of Veterinary Medicine, The Ohio State University, Columbus, Ohio.
Rikki CanniotoDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York.
Alyssa I ClayCancer Genetic Epidemiology, Division of Epidemiology, Mayo Clinic, Rochester, Minnesota.
John Lewis EtterDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York.
Kevin H EngDepartment of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, New York.
Song LiuDepartment of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, New York.
Sebastiano BattagliaDepartment of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, New York.
Qiang HuDepartment of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, New York.
J Brian SzenderGynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York.
Albina MinlikeevaDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York.
Janine M JosephDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York.
Paul MayorGynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York.
Scott I AbramsDepartment of Immunology, Roswell Park Cancer Institute, Buffalo, New York.
Brahm H SegalDepartment of Immunology, Roswell Park Cancer Institute, Buffalo, New York.
Paul K WallaceDepartment of Flow & Image Cytometry, Roswell Park Cancer Institute, Buffalo, New York.
Kah Teong SohDepartment of Flow & Image Cytometry, Roswell Park Cancer Institute, Buffalo, New York.
Emese ZsirosGynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York.
Hoda Anton-CulverGenetic Epidemiology Research Institute, School of Medicine, University of California Irvine, Irvine, California.
Elisa V BanderaCancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
Matthias W BeckmannDepartment of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Andrew BerchuckDepartment of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina.
Line BjorgeDepartment of Gynecology and Obstetrics, Haukeland University Horpital, Bergen, Norway.
Amanda BrueglDepartment of Obstetrics & Gynecology, Oregon Health & Science University, Portland, Oregon.
Ian G CampbellCancer Genetics Laboratory, East Melbourne, Australia.
Shawn Patrice CampbellDepartment of Obstetrics & Gynecology, Oregon Health & Science University, Portland, Oregon.
Georgia Chenevix-Trench
Daniel W CramerObstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Massachusetts.
Agnieszka Dansonka-MieszkowskaDepartment of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
Fanny DaoGynecologic Oncology, Laura and Isaac Pearlmutter Cancer Center, NYU Langone Medical Center, New York, New York.
Brenda DiergaardeDepartment of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania.
Thilo DoerkDepartment of Obstetrics and Gynecology, Hannover Medical School, Hannover, Niedersachsen, Germany.
Jennifer A DohertyDepartment of Epidemiology, The Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire.
Andreas du BoisDepartment of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany.
Diana EcclesFaculty of Medicine, University of Southampton, Southampton, United Kingdom.
Svend Aage EngelholmDepartment of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Peter A FaschingDepartment of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Simon A GaytherCenter for Cancer Prevention and Translational Genomics, Cedars-Sinai Medical Center, Los Angeles, California.
Aleksandra Gentry-MaharajWomen's Cancer, Institute for Women's Health, University College London, London, United Kingdom.
Rosalind M GlasspoolThe Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.
Marc T GoodmanCancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Jacek GronwaldDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
Philipp HarterDepartment of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany.
Alexander HeinDepartment of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Florian HeitzDepartment of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte/Evang. Huyssens-Stiftung/Knappschaft GmbH, Essen, Germany.
Peter HillemmannsDepartment of Obstetrics and Gynecology, Hannover Medical School, Hannover, Niedersachsen, Germany.
Claus HøgdallDepartment of Gynaecology, Rigshospitalet, University of Copenhagen, Herlev, Denmark.
Estrid V S HøgdallDepartment of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
Tomasz HuzarskiDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
Allan JensenDepartment of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark.
Sharon E JohnattyGenetics and Computational Biology Department, QIMR Berghofer Medical Research Institute, Herston, Australia.
Audrey JungDivision of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
Beth Y KarlanWomen's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Reudiger KlapdorDepartment of Obstetrics and Gynecology, Hannover Medical School, Hannover, Niedersachsen, Germany.
Tomasz KluzClinic of Obstetrics and Gynecology, Institute of Midwifery and Emergency Medicine, Faculty of Medicine, University of Rzeszów, Rzeszów, Poland.
Bożena KonopkaDepartment of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
Susanne Krüger KjærDepartment of Gynaecology, Rigshospitalet, University of Copenhagen, Herlev, Denmark.
Jolanta KupryjanczykDepartment of Pathology and Laboratory Diagnostics, the Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
Diether LambrechtsDepartment of Oncology, Laboratory for Translational Genetics, Vesalius Research Center, University of Leuven, Leuven, Belgium.
Jenny LesterWomen's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Jan LubińskiDepartment of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
Douglas A LevineGynecologic Oncology, Laura and Isaac Pearlmutter Cancer Center, NYU Langone Medical Center, New York, New York.
Lene LundvallDepartment of Gynecology, The Juliane Marie Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Valerie McGuireDepartment of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, California.
Iain A McNeishInstitute of Cancer Sciences, University of Glasgow, Wolfson Wohl Cancer Research Centre, Beatson Institute for Cancer Research, Glasgow, United Kingdom.
Usha MenonWomen's Cancer, Institute for Women's Health, University College London, London, United Kingdom.
Francesmary ModugnoDepartment of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania.
Roberta B NessThe University of Texas School of Public Health, Houston, Texas.
Sandra OrsulicWomen's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
James PaulThe Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom.
Celeste Leigh PearceDepartment of Epidemiology, University of Michigan School of Public Health, Ann Arbor, Michigan.
Tanja PejovicDepartment of Obstetrics & Gynecology, Oregon Health & Science University, Portland, Oregon.
Paul PharoahDepartment of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom.
Susan J RamusSchool of Women's and Children's Health, University of New South Wales, New South Wales, Australia.
Joseph RothsteinDepartment of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, California.
Mary Anne RossingProgram in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Matthias RübnerDepartment of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Joellen M SchildkrautDepartment of Public Health Sciences, The University of Virginia, Charlottesville, Virginia.
Barbara SchmalfeldtDepartment of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Ira SchwaabPraxis für Humangenetik, Wiesbaden, Germany.
Nadeem SiddiquiDepartment of Gynaecological Oncology, Glasgow Royal Infirmary, Glasgow, United Kingdom.
Weiva SiehDepartment of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York.
Piotr SobiczewskiDepartment of Gynecologic Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.
Honglin SongDepartment of Oncology, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom.
Kathryn L TerryObstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, Massachusetts.
Els Van NieuwenhuysenDivision of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
Adriaan VandersticheleDivision of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
Ignace VergoteDivision of Gynecologic Oncology, Department of Obstetrics and Gynaecology and Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
Christine S WalshWomen's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Penelope M WebbPopulation Health Department, QIMR Berghofer Medical Research Institute, Herston, Australia.
Nicolas WentzensenDivision of Cancer Epidemiology and Genetics, NCI, Bethesda, Maryland.
Alice S WhittemoreDepartment of Health Research and Policy - Epidemiology, Stanford University School of Medicine, Stanford, California.
Anna H WuDepartment of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
Argyrios ZiogasDepartment of Epidemiology, University of California Irvine, Irvine, California.
Kunle OdunsiGynecologic Oncology, Roswell Park Cancer Institute, Buffalo, New York.
Jenny Chang-ClaudeDivision of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
Ellen L GoodeDepartment of Health Science Research, Mayo Clinic, Rochester, Minnesota.
Kirsten B MoysichDepartment of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York. kirsten.moysich@roswellpark.org.
Australian Ovarian Cancer Study
Roswell Park Comprehensive Cancer Center · US
Funding
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4MWomen's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3MTwo-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6MTRANSCRIPTIONAL PROFILINGP30CA072720 · NCI · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI Chang S Chan · 1997 to 2026
$94.5MUCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0MUse of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0MWITHIN SUBJ VARIABILITY IN MEASUREMENTS DRUG METABOL ENZYMES IN HLTY SUBJM01RR000056 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEVINE, ARTHUR S · 1985 to 2006
$29.2MNorthern California Cooperative Family Registry for Breast CancerU01CA069417 · NCI · NORTHERN CALIFORNIA CANCER CENTER · PI JOHN, ESTHER M. · 1995 to 2010
$22.4MRPCI-UPCI Ovarian Cancer SPOREP50CA159981 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MOYSICH, KIRSTEN B. · 2013 to 2025
$19.6MUSC CANCER EPIDEMIOLOGY &BIOSTATISTICS UNITP01CA017054 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI DEAPEN, DENNIS M. · 1985 to 2009
$18.2MNovel Serum, Plasma, and Urine Biomarkers of Ovarian CanP50CA105009 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI CRAMER, DANIEL WILLIAM · 2004 to 2010
$13.3MTraining Program in Cellular and Molecular MedicineT32GM008752 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI RAO, RAJINI · 2000 to 2019
$11.7MCancer Research UK 10119Cancer Research UK 10124Cancer Research UK 16561Medical Research Council G0501974NCATS NIH HHS UL1 TR000124NCI NIH HHS K07 CA080668NCI NIH HHS K07 CA095666NCI NIH HHS K07 CA143047NCI NIH HHS K22 CA138563NCI NIH HHS N01 CN025403NCI NIH HHS N01 PC067010NCI NIH HHS P01 CA017054NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA016056NCI NIH HHS P30 CA072720NCI NIH HHS P50 CA105009NCI NIH HHS P50 CA136393NCI NIH HHS P50 CA159981NCI NIH HHS R01 CA054419NCI NIH HHS R01 CA058598NCI NIH HHS R01 CA058860NCI NIH HHS R01 CA076016NCI NIH HHS R01 CA087538NCI NIH HHS R01 CA095023NCI NIH HHS R01 CA112523NCI NIH HHS R01 CA122443NCI NIH HHS R01 CA126841NCI NIH HHS R01 CA140622NCI NIH HHS R01 CA188900NCI NIH HHS R03 CA113148NCI NIH HHS R03 CA115195NCI NIH HHS R25 CA092049NCI NIH HHS R25 CA113951NCI NIH HHS T32 CA108456NCI NIH HHS U01 CA069417NCRR NIH HHS M01 RR000056NIGMS NIH HHS T32 GM008752
Abstract
PubMed holds no abstract for this paper.
Indexed as
Genetic VariationCarcinoma, Ovarian EpithelialFemaleGenetic Association StudiesHumansMyeloid-Derived Suppressor CellsNeoplasms, Glandular and EpithelialOvarian Neoplasms
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.